Premium
Arterial chemoradiotherapy for carcinomas of the external auditory canal and middle ear
Author(s) -
Fujiwara Masayuki,
Yamamoto Satoshi,
Doi Hiroshi,
Takada Yasuhiro,
Odawara Soichi,
Niwa Yasue,
Ishikura Reiichi,
Kamikonya Norihiko,
Terada Tomonori,
Uwa Nobuhiro,
Sagawa Kosuke,
Hirota Shozo
Publication year - 2015
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.24908
Subject(s) - medicine , middle ear , chemoradiotherapy , auditory canal , radiation therapy , surgery , adverse effect , survival rate , retrospective cohort study , ear canal , radiology
Objectives/Hypothesis The purpose of this study was to estimate the efficacy of superselective arterial chemoradiotherapy for locally advanced carcinomas of the external auditory canal and middle ear. Study Design A retrospective study of clinical data for consecutive patients with locally advanced carcinomas of the external auditory canal and middle ear. Methods Thirteen patients with locally advanced carcinomas of the external auditory canal and middle ear (T3: one patient, T4: 12 patients) were reviewed. The median follow‐up duration in the living patients was 33 months. The total dose of radiation therapy was 60 Gy using conventional fractionation. Four, five, or six courses of a superselective arterial infusion (cisplatin 50 mg) were given weekly. Results The overall survival and progression‐free survival rates at 2 years, calculated by the Kaplan‐Meier method, were 58.7% and 53.8%, respectively. No late‐phase adverse effects due to chemoradiation and no adverse effects due to catheterization were observed. Conclusions These results suggest that superselective arterial chemoradiation can be a treatment option for locally advanced carcinomas of the external auditory canal and middle ear. Level of Evidence 4 Laryngoscope , 125:685–689, 2015